Increased prevalence of regurgitant valvular heart disease in acromegaly.

Cardiac involvement is common in acromegaly, but the prevalence of valvular abnormalities in patients with acromegaly has not been documented and is the topic of this study. In a prospective study design, 40 consecutive patients with acromegaly and 120 control subjects (matched for age, sex, hypertension, and left ventricular systolic function) were studied. All patients and controls were evaluated using conventional two-dimensional and Doppler echocardiography. Significant valve disease was more prevalent in acromegalics compared with controls (22% vs. 6.7%, respectively; P = 0.005). Aortic valve regurgitation (>/=>trace severity) was present in 30% of patients vs. 7% of controls (P < 0.001), and mitral regurgitation (>/=moderate severity) was absent in controls but present in 5% of acromegalics (P = 0.014 vs. controls). Binary logistic regression analysis showed a significant impact only for disease duration on valvular disease, with an odds ratio of 1.19 (95% confidence interval, 1.028-1.376; P = 0.019). Acromegaly is associated with an increased prevalence of regurgitant valvular heart disease. This is dependent on the duration of exposure to increased GH concentrations, with a 19% increase in odds per year. This increased prevalence of occult valvular disease indicates that these patients require appropriate follow-up care and monitoring, especially patients with inadequate control of GH overproduction.

[1]  D. Bonaduce,et al.  High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study. , 2003, The Journal of clinical endocrinology and metabolism.

[2]  C. Mady,et al.  Treatment of acromegaly improves myocardial abnormalities. , 2002, American heart journal.

[3]  P. Libby,et al.  Activated Interstitial Myofibroblasts Express Catabolic Enzymes and Mediate Matrix Remodeling in Myxomatous Heart Valves , 2001, Circulation.

[4]  E. Creemers,et al.  This Review Is Part of a Thematic Series on Matrix Metalloproteinases, Which Includes the following Articles: Matrix Metalloproteinase Inhibition after Myocardial Infarction: a New Approach to Prevent Heart Failure? Matrix Metalloproteinase: Regulation and Dysregulation in the failing Heart Matrix M , 2022 .

[5]  S. Tyagi,et al.  Activation of matrix metalloproteinase dilates and decreases cardiac tensile strength. , 2001, International journal of cardiology.

[6]  B. Howard,et al.  Reference values for echocardiographic measurements in urban and rural populations of differing ethnicity: the Strong Heart Study. , 2001, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[7]  B. Thompson,et al.  Identification of genes induced by growth hormone in rat liver using cDNA arrays. , 2000, Endocrinology.

[8]  J. Shirani,et al.  Matrix metalloproteinase expression in nonrheumatic aortic stenosis. , 2000, Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology.

[9]  F. Franco,et al.  Acromegalia asociada a prolapso mitral y tricuspídeo. Descripción de un caso , 2000 .

[10]  F. Sánchez Franco,et al.  [Acromegaly associated with mitral and tricuspid prolapse. Report of a case]. , 2000, Revista espanola de cardiologia.

[11]  A. Burger,et al.  Low prevalence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. , 1999, Journal of the American College of Cardiology.

[12]  M. Salvatore,et al.  Impact of patient's age and disease duration on cardiac performance in acromegaly: a radionuclide angiography study. , 1999, The Journal of clinical endocrinology and metabolism.

[13]  Jagmeet P. Singh,et al.  Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study) , 1999, The American journal of cardiology.

[14]  A. Colao,et al.  Bone mineral density and circulating cytokines in patients with acromegaly , 1998, Journal of endocrinological investigation.

[15]  N. Weissman,et al.  An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. , 1998, The New England journal of medicine.

[16]  Y. Tomizawa,et al.  Heart valve operation in acromegaly. , 1997, The Annals of thoracic surgery.

[17]  P. Marzullo,et al.  Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. , 1997, The Journal of endocrinology.

[18]  P. Wrightson,et al.  Determinants of clinical outcome and survival in acromegaly , 1994, Clinical endocrinology.

[19]  K. Isaaz,et al.  A simplified normalized ejection phase index measured by Doppler echocardiography for the assessment of left ventricular performance. , 1990, The American journal of cardiology.

[20]  N C Nanda,et al.  Evaluation of aortic insufficiency by Doppler color flow mapping. , 1987, Journal of the American College of Cardiology.

[21]  N. Nanda,et al.  Color Doppler assessment of mitral regurgitation with orthogonal planes. , 1987, Circulation.

[22]  A. Jaffe,et al.  Mitral Valve Prolapse: A Consistent Manifestation of Type IV Ehlers‐Danlos Syndrome The Pathogenetic Role of the Abnormal Production of Type III Collagen , 1981, Circulation.